We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Anticancer Drug Derived from Blue-Green Algae

By Biotechdaily staff writers
Posted on 28 Feb 2008
A collaborative team of researchers has identified a potent new anti-cancer drug isolated from a toxic blue-green algae found in the South Pacific. More...


The properties of somocystinamide A (ScA) were recently described in an article published online in the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS) the week of February 11-15, 2008. "We are excited because we have discovered a structurally unique and highly potent cancer-fighting compound,” said Dr. Dwayne G. Stupack, associate professor of pathology at the Moores University of California, San Diego (UCSD) Cancer Center (USA). "We envision it will be perfect for emerging technology, particularly nanotechnology, which is being developed to target cancerous tumors without toxic side effects.”

The ScA compound was found in the cyanobacteria Lyngbya majuscula, also known as "mermaid's hair,” collected off the coast of Fiji in the South Pacific by the laboratory of William Gerwick at Scripps Institution of Oceanography. A diverse team of researchers from UCSD's Cancer Center, and other institutions worked to identify, screen, and test marine compounds in vitro and in vivo. They found that ScA suppresses neovascularization, the formation of blood vessels that feed tumors, and had a direct impact on tumor cell proliferation.

"The compound isn't toxic to the cyanobacteria itself, but activates a ‘death pathway,' present in our cells,” said Dr. Stupack. "When the cells of the blood vessels that feed tumors become activated and proliferate, they become especially sensitive to this agent.” Dr. Gerwick noted that if a normal-sized swimming pool full of cancer cells were treated with ScA, it would take only 3 mg, about the weight of a grain of rice to kill all of the cancer cells.

Wolf Wrasidlo, Ph.D., senior project scientist at the Moores UCSD Cancer Center and first author of the study, added that the unique structure of this compound lends itself very well to nanotechnology, because it "incorporates spontaneously” into molecule-sized nanoparticles, important for the kind of highly targeted, combination therapy being developed to treat cancer. The structure is also simple enough that the scientists can reproduce it.

"ScA is the first, and most potent compound we've identified so far,” Dr. Stupack said, adding that it will not be the last, as the team has identified more than 250 unique compounds from L. majuscula alone. "But we don't yet know how abundant ScA is, or if it's feasible to harvest, so it is important that we have been able to produce this natural product in the lab.”


Related Links:
Rebecca and John Moores UCSD Cancer Center

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.